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Abstract
Background: Cationic bilayers based on the inexpensive synthetic lipid dioctadecyldimethylammonium bromide
(DODAB) have been useful as carriers for drug delivery, immunoadjuvants for vaccines and active antimicrobial agents.
Methods: Rifampicin (RIF) or isoniazid (ISO) interacted with DODAB bilayer fragments (BF) or large vesicles (LV).
Dispersions were evaluated by dynamic light-scattering for zeta-average diameter (Dz) and zeta-potential (ζ)
analysis; dialysis for determination of drug entrapment efficiency; plating and CFU counting for determination of
cell viability of Mycobacterium smegmatis or tuberculosis, minimal bactericidal concentration (MBC) and synergism
index for DODAB/drug combinations.
Results: DODAB alone killed micobacteria over a range of micromolar concentrations. RIF aggregates in water
solution were solubilised by DODAB BF. RIF was incorporated in DODAB bilayers at high percentiles in contrast to
the leaky behavior of ISO. Combination DODAB/RIF yielded MBCs of 2/2 and 4/0.007 μg/mL against Mycobacterium
smegmatis or Mycobacterium tuberculosis, respectively. Synergism indexes equal to 0.5 or 1.0, indicated synergism
against the former and independent action, against the latter species.
Conclusions: In vitro, DODAB acted effectively both as micobactericidal agent and carrier for rifampicin. The novel
assemblies at reduced doses may become valuable against tuberculosis.
Background
Tuberculosis (TB) is a curable infectious disease affect-
ing mostly the lungs which is caused by Mycobacterium
tuberculosis. In 2008, an increase of 9.3 million novel
TB cases was reported, since the slow reduction in inci-
dence rates per capita continues to be surpassed by
increasing world population [1]. Control of TB remains
a serious challenge for public health due to the emer-
gence of mutated strains presenting resistance to at least
the two major anti-tuberculosis drugs, isoniazid and
rifampicin [2]. Treatment of multidrug resistant TB
requires prolonged and expensive chemotherapy using
highly toxic, second-line drugs [2]. Eventually, resistance
to these second line drugs develops and the disease
becomes untreatable [2]. Clearly, there is an urgent need
to improve treatment by either enhancing the applica-
tion of existing agents or introducing new drugs. Thus,
it is important to develop not only new drug candidates
and drug targets but also delivery systems.
Cationic bilayers based on dioctadecyldimethylammo-
nium bromide (DODAB) have been useful as carriers in
drug delivery [3], immunoadjuvants for vaccines [4,5] and
as antimicrobial agents due to their quaternary ammonium
moiety [6]. In this work, the ability of such bilayers to
incorporate and deliver antitubercular drugs such as rifam-
picin (RIF) and isoniazid (ISO) in vitro was investigated
and assemblies tested against two Mycobacterium species.
The results evidenced the micobactericidal activity in vitro
of DODAB alone or in combination with rifampicin.
Methods
Materials
DODAB 99.9% pure, dipalmitoylphosphatidylcholine
(DPPC) and asolecitin (ASO) were obtained from Sigma
(USA) and used as such without further purification. RIF
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drous D-glucose was from Merck (Darmstadt, Germany)
and water was Milli-Q quality. Chemical structures of
DODAB, RIF and ISO were shown in Figure 1.
Preparation of DODAB dispersions
Lipids were dispersed in water or 0.264 M D- glucose
solution. DODAB bilayer fragments (BF) were prepared
by sonication with tip above the gel-to-liquid-crystalline
bilayer phase transition temperature [7,8]. This proce-
dure dispersed the amphiphile powder in water using a
high-energy input, which not only produced bilayer vesi-
cles but also disrupted these vesicles, thereby generating
open BF. DODAB was alternatively dispersed by vortex-
ing at 60°C to obtain LV. DODAB analytical concentra-
tion was determined by bromide microtitration [9].
Determination of size distribution, zeta-average diameter
and zeta-potential for dispersions
The size distributions for DODAB, RIF and DODAB/
RIF were determined by means of a zeta-potential analy-
ser (ZetaPlus-Brookhaven Instruments Corporation,
Holtsville, NY, USA) equipped with a 570 nm laser and
dynamic light scattering at 90° for particle sizing [10].
The zeta-average diameter (Dz) referred to in this work
should be understood as the mean hydrodynamic dia-
meter. Zeta-potentials (ζ) were determined from the
electrophoretic mobility μ and Smoluchowski’s equation,
ζ = μh/ε,w h e r eh and ε are medium viscosity and
dielectric constant, respectively. All Dz and ζ were
obtained at 25°C, 1 h after mixing.
Determination of RIF or ISO optical spectra in different
media
RIF or ISO optical spectra were determined using a
Hitachi 2000 spectrophotometer in the double-beam
mode against a blank of lipid dispersions and solvent
(without drug). RIF and ISO stock solutions were pre-
pared at 1 mg/mL in dimethylsulfoxide (DMSO) and
water, respectively. RIF spectra were obtained by adding
RIF stock solution to water, DMSO, DODAB BF or
DODAB LV. ISO spectra were obtained by adding the
stock solution to water or DODAB LV dispersions. All
optical spectra were obtained at 25° C just after mixing.
Figure 1 Chemical structures of DODAB cationic lipid and antitubercular drugs RIF and ISO. The chemical structures of isoniazid (ISO),
rifampicin (RIF) and dioctadecildimetilamonium bromide (DODAB).
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different media plus drug molar absorptivity were deter-
mined from analysis of optical spectra.
Determination of entrapment efficiency for RIF in DODAB
dispersions
DODAB LV or BF were obtained in a 0.1 mM RIF and
0.264 M D-glucose solution. Aliquots of 2 mL of the RIF
solution (control) and DODAB BF or LV (at 2 mM
DODAB) prepared in this RIF solution were dialyzed
against (4X) 250 mL of 0.264 M D-glucose solution for
24 h. Thereafter, aliquots of RIF solution, DODAB LV/RIF
or DODAB BF/RIF before and after dialysis were added of
ethanol (50%) in order to solubilize the DODAB bilayers.
RIF concentration was determined spectrophotometrically
from absorbance at 334 nm. Drug incorporation percentile
(% Inc) was given by equation (1):
%Inc = 100 ×

A2/A1

−

A2c/A1c

(1)
Where A1 and A2 are absorbances of RIF/DODAB LV
or RIF/DODAB BF before and after dialysis, respectively;
A 1c and A 2c are absorbances of RIF solution before and
after dialysis. Since % Inc depends on DODAB concen-
tration, % Inc was normalized to DODAB concentration
yielding entrapment efficiency (ENT) from equation (2):
ENT = % Inc/(100 [DODAB]) (2)
ENT in L/mol depends only on physical characteristics
of the liposomal dispersion such as size and lamelarity
but does not depend on lipid concentration.
Determination of ISO entrapment efficiency in DODAB,
asolecithin (ASO) or DODAB/DPPC 1:1 dispersions
DODAB LV were prepared in a 0.1 mM ISO solution at
2 mM DODAB. Large DODAB/DPPC vesicles were pre-
pared by spreading and evaporating a chloroform solu-
tion of lipids on the bottom of a glass tube [11]. Briefly,
films of DODAB/DPPC at 2 mM total lipid were pre-
pared from stock chloroform solutions of the lipids by
evaporating the solvent under N2 flux. In order to
remove the residual solvent, the films remained under
vacuum overnight at room temperature. Vesicles were
prepared by hydrating the films with 0.1 mM ISO water
solution at 60° C and vortexing dispersions until they
became homogeneous. Asolecitin lipids at 2 mM total
lipid were dispersed by vortexing at room temperature to
obtain multilamellar vesicles (MLV) in the same 0.1 mM
ISO solution [12]. The dialysis procedure employed to
determine ISO entrapment in the three different lipid dis-
persions was similar to the one described for RIF in the
previous item. Dialysis was carried out against water for
12 h. After dialysis, the ISO contents inside each bag
were evaluated at 260 nm after liposomes lysis either by
adding ethanol (50%) or Triton X-100 (1%). % Inc and
ENT were calculated as described in the previous section.
Microrganisms and culture conditions
M. smegmatis (ATCC mc2155) and M. tuberculosis
(ATCC 27294) were obtained from Mycobacterial
Laboratory culture collection of the Universidade de São
Paulo. M. smegmatis was cultured freshly on Muller
Hinton Agar (MHA) plates for 72 h at 30°C. Thereafter,
one or two colonies were transferred to 10 mL Middleb-
rook 7H9 broth and incubated in a shaker (150 rpm/30°
C/48 h). M. tuberculosis was cultured freshly on Lowen-
stein- Jensen (BBL™ - Becton Dickinson Microbiology
System, Sparks, MD, USA) agar for 28 days at 37° C.
Thereafter, one or two colonies were transferred to
10 mL of Middlebrook 7H9 culture medium supplemen-
ted with 10% oleic acid albumin dextrose complex
(OADC) and 0.2% glycerin and incubated at 37° C for 7-
10 days to reach exponential growth. Cultures were then
pelleted (6000 rpm/15 min) and washed in a 0.264 M D-
glucose solution as an osmoprotectant [13]. The washing
procedure was repeated twice before adjusting turbidity
to 1 of the McFarland scale.
Viability assays for M. smegmatis and M. tuberculosis in
the presence of DODAB dispersions
Cell viability was determined after incubation of cells (5 ×
10
6 CFU/mL) with DODAB dispersions over a range of
concentrations (0-1 mM DODAB) for 1 h in the case of
M. smegmatis or 7 days for M. tuberculosis. The positive
control was performed at DODAB concentration equal to
zero. After interaction between cells and DODAB, serial
dilution (10
-1 to 10
-4) of each tube using a solution of
D-glucose 0.264 M yielded 500 CFU/mL from which 100
μL were taken and plated in duplicate on MHA plates,
before incubation (72 h/30°C) for M. smegmatis. Plating
for M. tuberculosis was made on Middlebrook 7H10 agar
supplemented with OADC and glycerol plates incubated
in 5% CO2, 10% humidity and 37°C for 3 - 4 weeks. CFU
counting was then performed and plotted as % cell viabi-
lity as a function of DODAB concentration.
Determination of minimal bactericidal concentration
(MBC) for RIF or DODAB against Mycobacterium
smegmatis and M. tuberculosis in 0.264 D-glucose solution
The medium used for diluting cells was D-glucose 0.264
M. Usually, evaluation of combined action of antimicrobial
drugs is performed from chequerboard experiments and
presented as the standard fractional inhibitory concentra-
tion index (FICI). Unfortunately, the chequerboard experi-
ment in the culture medium is not feasible for cationic
DODAB, which cannot remain in dispersion at usual ionic
strengths of the culture medium. DODAB dispersions floc-
culated at very low ionic strength (at and above 5 mM
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the culture medium [3]. This explained the use of the iso-
tonic D-glucose solution for MIC determination. Briefly,
for M. smegmatis twofold serial dilutions of RIF, and
DODAB BF were prepared at final volume of 1 mL
per tube. The final concentration of the antimicrobial
agents ranged from 512 to 1 μg/mL for RIF and from
512 to 1 μg/mL for DODAB BF. Each tube was inoculated
with bacterial cell suspension to a final concentration of
10
4 cells per tube and the plates were incubated at 30°C for
72 h. An aliquot 0.1 mL was taken from each tube, diluted
1:10 and 1:100, and cell viability was determined by plating
0.1 mL of each dilution on MHA plates in duplicate and
incubating for 72 h at 30°C. The MIC endpoint was the
lowest drug concentration that killed ≥ 99.9% of the inocu-
lum. For M. tuberculosis drugs were diluted in microplates
in a solution of D-glucose in concentrations ranging from
1-0.0039 or 512-1 μg/mL for RIF and DODAB, respec-
tively, in a volume of 100 μl per well. After drugs dilution,
each well was inoculated with 100 μl of the standardized
bacterial suspension (10
5 CFU/mL). The plates were incu-
bated at 37°C, 5% CO2 and 10% humidity for 7 days. An
aliquot was removed from each well diluted 1:10 and 1:100
dilution and 50 μl were plated on 7H10 ágar. The plates
were then incubated at 37°C, 5% CO2, 10% humidity,
3-4 weeks. MBC was determined as the lowest drug con-
centration that killed ≥ 90% of the bacterial inoculum.
Determination of fractional inhibitory concentration index
(FICI) for combinations of DODAB and RIF dispersions
against M. smegmatis and M. tuberculosis
Twofold serial dilutions of RIF solutions or DODAB dis-
persions were distributed in tubes, in order to obtain
final concentrations ranging from 512 to 1 μg/mL RIF or
DODAB after interaction with cells. Thereafter, RIF
diluted solutions were added of DODAB BF dispersion to
yield a final DODAB concentration of 2 μg/mL after
interaction with cells. Similarly the DODAB BF diluted
dispersions were added of RIF solution to yield a final
RIF concentration of 2 μg/mL after interaction with cells.
Drug-lipid mixtures were incubated together for 1 h
before adding the cell suspension. Each tube was inocu-
lated with M. smegmatis cell suspension to yield
10
4 cells/tube and incubated at 30°C for 72 h. Thereafter,
an aliquot of 0.1 mL was diluted 1:10 and 1:100, and cell
viability was determined by plating and incubation for
72 h, 30°C. The lowest drug concentration that killed
≥ 99.9% of the inoculum was used to determine the frac-
tional inhibitory concentration (FIC), defined as the ratio
of the MBC of a drug used in combination with the MBC
of the drug tested alone. The FIC index (FICI) was calcu-
lated as the sum of the FICs for the most equally effective
c o n c e n t r a t i o no fd r u g s .A c c o r d i n gt oO d d s ,F I C I≤ 0.5
corresponds to drug synergism, whereas an index > 4.0
represents antagonism [14]. Each experiment was carried
out in duplicate and no variation was obtained among
them. The microplate was used for the test of synergism
between DODAB/BF and RIF against M. tuberculosis.
A serial dilution of RIF was performed to yield final con-
centrations over the 1-0.0039 μg/mL range in 50 μLp e r
well. Each well containing RIF dilutions was added of
50 μLo fa4μg/mL DODAB dispersion. Furthermore,
serial dilutions of DODAB BF (512-1 μg/mL) in 50 μL
per well were added of RIF at 0.0078 μg/mL (a concen-
tration value lower than MBC). RIF and DODAB BF
w e r em i x e da n da l l o w e dt oi n t e r a c tf o r1h o u rb e f o r e
addition of bacterial cells. In each tube 100 μLo ft h e
standardized bacterial suspension (10
5 CFU/mL) was
added. The microplates were then incubated (37°C, 5%
CO2, 10% humidity,7 days). An aliquot of each well was
diluted 1:10 and 1:100, 50 μL of the final dilution was
plated on 7H10 agar and incubated (37°C, 5% CO2,1 0 %
humidity, 3-4 weeks). MBC was determined as the lowest
drug concentration that killed ≥ 90% of the bacterial
inoculum.
Results
Physico-chemical characterization of drug/DODAB
assemblies
The solubility limit for RIF in water is 1.3 mg/mL or
1 . 6m M .A b o v et h i sl i m i tt h ed r u ga g g r e g a t e si nw a t e r
solution. Optical spectra for the drug in different media
such as water, DODAB BF or DODAB LV were similar to
those for RIF in its best organic solvent, DMSO (Figure 2).
Absorption maxima for the drug in water occurred at
smaller wavelengths than those for RIF in its best organic
solvent DMSO or in the DODAB dispersions (Table 1). In
the presence of DODAB bilayers, the drug displayed
absorption maxima at wavelengths practically equal to the
one in its best organic solvent DMSO. The molar absorp-
tivity (ε) of the drug in DMSO was 15,130 M
-1cm
-1. Simi-
l a rv a l u e so c c u r r e di nD O D A Bd i s p e r s i o n s( T a b l e1 ) .
Figure 3 showed the size distribution for DODAB BF at
0.5 mM DODAB in water (Figure 3A), 2 mM RIF in water
(Figure 3B), and 2 mM RIF in DODAB BF (0.5 mM
DODAB) (Figure 3C). Mean particle size for drug disper-
s i o na t2m MR I Fw a s7 6 0±2 0n mw h e r e a st h ez e t a -
potential was 0 mV ± 10. When solubilized in the bilayer
fragment, Dz was 89 ± 1 nm and zeta potential, 26 ±
1 mV (Figure 3C). This size was the same obtained for
DODAB BF in the absence of drug 86 ± 2 nm. The zeta-
potential of (26 ± 1 mV) was lower than the one in
absence of drug (61 ± 1 mV) (Figure 3C).
Optical spectra for ISO in water were not affected by
DODAB LV or BF (Figure 4). Its single absorption peak
around 260 nm in water remained unchanged in the
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in water or DODAB LV were also similar, 2,995 and
2,717 M
-1 cm
-1, respectively, again suggesting that ISO
was not incorporated in the DODAB bilayer.
Table 2 showed absorbance values at 334 nm before
and after dialysis in an experiment designed to determine
RIF incorporation in DODAB dispersions. The control
showed that RIF permeated freely through the dialysis
membrane. For DODAB LV/RIF, the majority of drug
molecules were retained inside the dialysis bag yielding
81% incorporation and ENT of 405 L/mol (Table 2). For
DODAB BF/RIF, entrapment efficiency was 375 L/mol, a
value slightly smaller than the one determined for
DODAB LV/RIF. This might have been due to the extra
amount of drug inside the vesicle aqueous compartment.
By means of an alternative technique such as ultracentri-
fugation, 77.3% incorporation in LV at 2 mM DODAB
was obtained. Total RIF concentration before ultracentri-
fugation was 0.075 mM. Thereafter only 0.017 mM
Figure 2 Solubilization of RIF aggregates in DODAB bilayer
fragments or LV. Light absorption spectra for RIF in: DMSO (A),
water (B), DODAB BF at 5 mM DODAB (C) and DODAB LV at 1 mM
DODAB (D). RIF final concentrations were 16 (a), 32 (b), 48 (c) and
64 μg/ml (d).
Table 1 The DODAB bilayer as a solubiliser for RIF
Solubilization medium l1max/nm l2max/nm ε at l1 max/M
-1cm
-1
DMSO 336 477 15,130
Water 331 468 13,890
DODAB BF 336 476 14,840
DODAB LV 334 476 15,000
Absorption maxima and molar absorptivities (ε) for RIF in different media.
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Figure 3 Solubilization of RIF aggregates in DODAB bilayer
fragments. Size distributions for DODAB BF in water at 0.5 mM
DODAB (A), RIF dispersion in water at 2 mM RIF (B) and mixture of
both at the same final concentrations (C). Zeta-average diameter
(Dz) and zeta-potential (ζ) are quoted in each subfigure.
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these two concentrations allowed the calculation of RIF
incorporated in the DODAB LV dispersion as 77.3% in
fair agreement with incorporation determined from
dialysis.
Dialysis experiments designed to determine ISO incor-
poration in DODAB dispersions revealed the leaky char-
acter of the DODAB LV towards ISO. After dialysis
overnight ISO incorporation fell to zero (Table3). Other
liposomes prepared from asolecithin or DODAB/DPPC
1:1 also yielded very low incorporation percentiles: 0%
ISO incorporation in DODAB/DPPC large vesicles or
0.01% incorporation in asolecithin multilamellar vesicles
after 12-24 h dialysis.
Micobactericidal activity of DODAB alone or combined
with rifampicin
The effect of DODAB concentration for DODAB dis-
persed as DODAB BF or LV on M. smegmatis at 3.5 ×
10
6 CFU/mL after 1 h interaction time is shown in
Figure 5. Micromolar DODAB concentrations were
effective against M. smegmatis. DODAB dispersed as LV
or BF affected the cells similarly. At 0.002 mM DODAB,
cell viability was 50%. After 120 h, 0.1 mM DODAB
completely killed M. tuberculosis (Figure 6).
Table4 showed MBC for RIF alone or in combination
with DODAB. The formulation DODAB/RIF yielded
ΣFIC = 0.5 evidencing synergism between DODAB and
RIF action against M. smegmatis.A g a i n s tM. tuberculo-
sis, ΣFIC = 1 suggested independent action for DODAB
and RIF in the combination.
Discussion
RIF was partially anionic (~ 40%) at pH 7.4 and electro-
statically interacted with the DODAB bilayer. The inser-
tion of RIF in the DODAB bilayer was supported by zeta-
potential decrease and could be understood from the
favourable electrostatic attraction between the partially
anionic RIF and the cationic bilayer which subsequently
drove the hydrophobic effect. This was consistent with
literature for other lipid bilayers loaded with RIF and
ofloxacin [15] or for RIF interactions with neutral dimyr-
istoil-L-a-phosphatidylcholine (DMPC) liposomes [16].
Together eletrostatics and hydrophobic effect solubilized
RIF in the DODAB bilayer yielding the very large entrap-
ment efficiency determined both for DODAB BF or
DODAB LV (Table 2). In fact, incorporation of RIF was
reported in various liposomal formulations such as dis-
persions of phosphatidylcholine (PC); dipalmitoylogly-
cero-PC (DPPC), distearoylglycero-PC (DSPC) with or
without cholesterol [17]. RIF incorporation was evaluated
in DPPC, DSPC or PC liposomes and reported at highest
in DPPC and DSPC bilayers [18]. Similarly to DPPC and
DSPC, DODAB also bears saturated hydrocarbon chains,
yielding optimal and high RIF incorporation (Table 2).
On the other hand, dialysis experiments showed that ISO
permeated freely through the DODAB LV bilayer. This
Figure 4 Isoniazid solubility in water. UV-VIS spectra of isoniazid
in: water (A), DODAB LV at 2 mM DODAB (B). ISO final
concentrations were: 10 (a), 20 (b), 30 (c) and 40 μg/ml (d).
Table 2 Eletrostatic attraction and hydrophobic effect
massively drove RIF to DODAB bilayers
Sample Abefore A after % Inc ENT(L/mol)
RIF 0.1 mM 1.98 ± 0.05 0.12 ± 0.05
DODAB LV 2 mM/RIF
0.1 mM
1.99 ± 0.05 1.62 ± 0.05 81 405
RIF 0.1 mM 2.30 ± 0.05 0.21 ± 0.05
DODAB BF 2 mM/RIF
0.1 mM
2.30 ± 0.05 1.75 ± 0.05 75 375
Rifampicin incorporation in DODAB dispersions from RIF absorbance at 334
nm (A) before and after dialysis.
Table 3 The leaky character of liposomal bilayers
towards isoniazid from dialysis experiments
Sample Abefore A after % Inc
ISO (0.1 mM control) 0.542 ± 0.010 0.061 ± 0.010 -
DODAB LV/ISO 0.1 mM 0.540 ± 0.010 0.052 ± 0.010 0
DODAB/DPPC 1:1/ISO 0.1 mM 0.504 ± 0.010 0.058 ± 0.010 0
ISO (10.0 mM control) 20.00 ± 0.010 0.017 ± 0.010 -
ASO MLV/ISO 10 mM 19.50 ± 0.010 0.400 ± 0.010 0.01
Isoniazid incorporation in DODAB, DODAB/DPPC 1:1 or asolecithin (ASO)
liposomal dispersions from ISO absorbance at 260 nm (A) before and after
dialysis. Final lipid concentration was 2.0 mM.
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posed of other lipids such as DODAB/DPPC 1:1 or asole-
cithin (ASO) multilamellar vesicles, though the
multilamellar assemblies yielded percentiles of incorpora-
tion slightly above zero (Table 3). ISO solubility in water
and permeability through the DODAB bilayer hampered
ISO incorporation in DODAB BF or DODAB LV. Sus-
tained release of ISO from DPPC multilamellar liposomes
was observed over 24 h [19]. This reconfirmed the high
permeability of this drug across phospholipid bilayers.
DODAB LV did not retain ISO inside their aqueous com-
partment after the12-24 h dialysis procedure.
The slightly smaller RIF entrapment efficiency for
DODAB BF in comparison to the one determined for
DODAB LV (Table 2) might have been due to the extra
amount of drug inside LV aqueous compartment which
was not available for the open DODAB BF. Reproducibility
of entrapment experiments was checked by ultracentrifu-
gation and results were shown to be very reproducible.
Other studies have shown that the covalent combina-
tion of drugs with hydrophobic moieties restored or
increased drug activity. Neomycin B had low activity
against strains of methicillin resistant S. aureus (MRSA)
and P. aeruginosa, whereas kanamycin A had low activity
against MRSA and methicillin resistant S. epidermidis
(MRSE) and P. aeruginosa. Recently, neomycin- or kana-
mycin A -cationic lipid conjugates were synthesized that
displayed high activity against both MRSA and MRSE,
respectively [20]. The conjugation of lipids increased the
activity of both aminoglycosides against resistant strains:
MIC for neomycin B against MRSA was 256 μg/mL. Its
conjugate bound to lipid had a MIC of 8 μg/mL [20].
Our results showed that the noncovalent combination of
RIF with the cationic lipid DODAB improved RIF anti-
bacterial activity, reducing MBC from 32 to 2 μg/mL
(Table 4). This work shows for the first time that drug-
DODAB self-assembly results in enhanced micobacterici-
dal activity at lower doses. These novel formulations may
find useful applications in clinics. The use of low doses
will possibly reduce drug toxicity in vivo.
Conclusions
Electrostatic attraction and hydrophobic effect
assembled RIF and DODAB bilayers yielding formula-
tions with micobactericidal activity at reduced DODAB
and RIF doses. DODAB by itself was also active against
Mycobacterium. The present study in vitro is a necessary
step before in vivo tests can be performed.
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Figure 5 Microbicidal effect of DODAB bilayers on M.
smegmatis. Cell viability (%) for M. smegmatis at 3.5 × 10
6 CFU/mL
as a function of DODAB concentration after 1 h of interaction time
with DODAB LV (circles) or BF (diamonds).
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Figure 6 Microbicidal effect of DODAB bilayers on M. tuberculosis.
Cell viability (%) for M. tuberculosis at 1.8 × 10
6 CFU/mL and 0.1 mM
DODAB as a function of interaction time with DODAB LV (diamonds)
or BF (squares).
Table 4 DODAB and DODAB/RIF killed Mycobacterium
MBC (μg/mL) FIC* ΣFIC**
Microrganism Drug Combination
32 (RIF) 2 (2 DODAB BF) 0.0625
M. smegmatis 4 (DODAB BF) 2 (2 RIF) 0.5 0.5
4 (DODAB LV) 2 (1 RIF) 0.5
0.015 (RIF) 0.007 (4 DODAB) 0.5
M. tuberculosis 8 (DODAB BF) 4 (0.007 RIF) 0.5 1
8 (DODAB LV) 4 (0.007 RIF) 0.5
Micobactericidal activity of RIF alone or in combination with DODAB.
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Page 7 of 8Dz: Zeta-average diameter; ζ: Zeta-potential; MBC: Minimal bactericidal
concentration; MIC: Minimal inhibitory concentration; TB: Tuberculosis; DPPC:
dipalmitoylphosphatidylcholine; ASO: asolecithin; DMSO: dimethylsulfoxide;
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